According to the NCI website, the splicing inhibitor H3B-8800 is an orally bioavailable inhibitor of the splicing factor 3B subunit 1 (SF3B1), with potential antineoplastic activity. Check for active clinical trials using this agent.  

More Information in English:
Link to National Cancer Institute